Aquestive Therapeutics (NASDAQ:AQST) Issues Quarterly Earnings Results

Posted by Sarita Garza on May 14th, 2025

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) announced its earnings results on Monday. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.07), Zacks reports. The company had revenue of $8.72 million for the quarter, compared to analysts’ expectations of $12.23 million. Aquestive Therapeutics updated its FY 2025 guidance to EPS.

Aquestive Therapeutics Price Performance

Aquestive Therapeutics stock opened at $2.29 on Wednesday. Aquestive Therapeutics has a 12-month low of $2.12 and a 12-month high of $5.80. The company has a market capitalization of $227.45 million, a price-to-earnings ratio of -5.09 and a beta of 2.02. The firm’s fifty day moving average price is $2.78 and its 200 day moving average price is $3.43.

Wall Street Analyst Weigh In

AQST has been the topic of a number of research analyst reports. Lake Street Capital decreased their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Alliance Global Partners reiterated a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Wednesday, April 2nd. Finally, Raymond James set a $7.00 price target on shares of Aquestive Therapeutics in a report on Friday, March 7th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $10.67.

Check Out Our Latest Stock Analysis on AQST

About Aquestive Therapeutics

(Get Free Report)

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.